Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cytokinetics Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Cytokinetics Inc trades at $77.39 (market cap $10.78B). The key difference: Cytokinetics Inc is far larger — about 2.1× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CYTK | |
|---|---|---|
Market Cap | $5.06B | $10.78B |
Sector | Health | Technology |
52-Week High | $29.41 | $87.26 |
52-Week Low | $20.06 | $34.31 |
Enterprise Value | $4.18B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
